Table 2 AbobotulinumtoxinA administration by treatment cycle
Treatment Cycle 1 | Treatment Cycle 2 | Treatment Cycle 3 | All Treatment Cycles | |
|---|---|---|---|---|
All patients, n | 112 | 97 | 93 | 112 |
Total dose, administered in Units, mean (SD) | 457.7 (75.3) | 507.1 (130.3) | 527.4 (166.8) | 1334.8 (476.9) |
Total dose <500 U, n (%) | 38 (33.9%) | 31 (32.0%) | 30 (32.3%) | – |
Total dose = 500 U, n (%) | 74 (66.1%) | 41 (42.3%) | 38 (40.9%) | – |
Total dose >500 U, n (%) | 0 | 25 (25.8%) | 25 (26.9%) | – |
Toxin-naïve patients, n | 35 | 31 | 30 | 35 |
Total dose, administered in Units, mean (SD) | 492.9 (34.2) | 549.5 (114.6) | 596.5 (192.4) | 1490.9 (468.6) |
Total dose <500 U, n (%) | 2 (5.7%) | 5 (16.1%) | 5 (16.7%) | – |
Total dose = 500 U, n (%) | 33 (94.3%) | 15 (48.4%) | 15 (50.0%) | – |
Total dose >500 U, n (%) | 0 | 11 (35.5%) | 10 (33.3%) | – |
Non-naïve patients, n | 77 | 66 | 63 | 77 |
Total dose, administered in Units, mean (SD) | 441.7 (83.2) | 487.1 (133.2) | 494.5 (143.4) | 1263.8 (466.5) |
Total dose <500 U, n (%) | 36 (46.8%) | 26 (39.4%) | 25 (39.7%) | – |
Total dose = 500 U, n (%) | 41 (53.2%) | 26 (39.4%) | 23 (36.5%) | – |
Total dose >500 U, n (%) | 0 | 14 (21.2%) | 15 (23.8%) | – |